Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538393 | 0.83 | DDB1 (0.53) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL30952401 | 0.81 | NAMPT (0.47) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL31323392 | 0.81 | DDB1 (0.48) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL31134480 | 0.81 | DDB1 (0.45) | NAMPTWNT3A | |
| SCHEMBL23120656 | 0.81 | NAMPT (0.52) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL24319286 | 0.81 | GRM1 (0.47) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL29223732 | 0.79 | PDK4 (0.46) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL31201927 | 0.79 | PDK4 (0.46) | NAMPTCDK7CDK13CDK12BRD4 | |
| SCHEMBL27168084 | 0.79 | DDB1 (0.50) | NAMPTWNT3A | |
| SCHEMBL29223716 | 0.79 | SCN9A (0.47) | NAMPTCDK7CDK13CDK12BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | NAMPT 3989/4885CDK7 1424/4885CDK13 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.